Clinical trial
A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene
NCT06447662 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene
- Lead sponsor
- Pfizer
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- June 27, 2024
- Completion date
- October 9, 2026
- Enrollment
- 64 (actual)
- Sites
- 27
Conditions
As the registry lists them; a condition with its own page is linked.